Thyroid-Associated Ophthalmopathy Clinical Trial
Official title:
New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression
The purpose of this study is to determine whether injection of autologous fat or hyaluronic-acid injections in temporal region are effective in the treatment of temporal hollowing after lateral wall decompression in patients with thyroid eye disease.
Grave's disease is one of the most common autoimmune diseases. Thyroid eye disease is affecting nearly 50% of patients with Grave's disease. Surgical treatment may address several of the manifestations, including the increased volume of the orbital contents. Decompression of the orbit can be achieved by removing the lateral orbital walls; "lateral wall decompression". In a retrospective study at the Department of Ophthalmology, Haukeland University Hospital, about half of the patients had a disfiguring hollowing in the temporal region after lateral wall decompression. The patient reported outcome of the procedure is clearly an indication for further esthetic treatment. However, until now the treatment option for these patients have been limited, or simply neglected. The investigators have contacted over 40 patients with this complication that want treatment. In this project the investigators will treat bilateral hollowing with injection of autologous fat in one temporal region and hyaluronic-acid injections on the opposite side. Participants with unilateral hollowing will be randomized to one of the treatment options. Outcomes will be evaluated by clinical examination, photographs and ultrasound volume measurement at 6, 12, 18 and 24 months postoperatively. The participants will be retreated at these follow up intervals if necessary. The project will be an interventional, prospective follow-up study and is approved by the regional ethics committee. The study will be the first of its kind to date as the investigators will be able to prospectively evaluate the effect of autologous fat injections to hyaluronic-acid injections in the same patient for the same condition. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03948191 -
99Tc-MDP for Thyroid-Associated Ophthalmopathy
|
Phase 4 | |
Completed |
NCT01599273 -
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
|
Phase 4 | |
Completed |
NCT01579539 -
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
|
Phase 3 | |
Recruiting |
NCT02203682 -
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
|
Phase 2 | |
Completed |
NCT01868997 -
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
|
Phase 2 | |
Terminated |
NCT00288522 -
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
|
Phase 2 | |
Recruiting |
NCT04936854 -
Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
|
Phase 2 | |
Completed |
NCT00595335 -
Trial of Rituximab for Graves' Ophthalmopathy
|
Phase 2/Phase 3 |